Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Publications

Recent publications published by researchers at the MRC WIMM.

Enhanced Immunogenicity of Mitochondrial-Localized Proteins in Cancer Cells.

Prota G. et al, (2020), Cancer Immunol Res, 8, 685 - 697

A highly accurate platform for clone-specific mutation discovery enables the study of active mutational processes.

KaramiNejadRanjbar M. et al, (2020), Elife, 9

Enhanced immunogenicity of mitochondrial localised proteins in cancer cells

CERUNDOLO V. et al, (2020), Cancer Immunology Research

Somatic mosaicism and common genetic variation contribute to the risk of very-early-onset inflammatory bowel disease.

Serra EG. et al, (2020), Nat Commun, 11

The Repertoire of Serous Ovarian Cancer Non-genetic Heterogeneity Revealed by Single-Cell Sequencing of Normal Fallopian Tube Epithelial Cells.

Hu Z. et al, (2020), Cancer Cell, 37, 226 - 242.e7

6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers.

Yang H. et al, (2019), Clin Cancer Res, 25, 5702 - 5716

Deep single-cell RNA-seq of the putative cell of origin revealed a novel molecular subtype of high-grade serous ovarian cancer with poor prognosis

Hu Z. et al, (2019), CANCER RESEARCH, 79

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference.

Bast RC. et al, (2019), Cancer, 125, 1963 - 1972

An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment.

Motohara T. et al, (2019), Oncogene, 38, 2885 - 2898

Tuning microtubule dynamics to enhance ovarian cancer therapy.

Zheng Y. et al, (2018), MOLECULAR BIOLOGY OF THE CELL, 29

Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials.

Vergote I. et al, (2018), Lancet Oncol, 19, 1680 - 1687

Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability.

Yang H. et al, (2018), Clin Cancer Res, 24, 5072 - 5084

Abstract IA07: Targeting micrometastasis for the treatment of ovarian cancer

Ahmed AA., (2018), Metabolic Changes in Ovarian Cancer

Targeting micrometastasis for the treatment of ovarian cancer.

Ahmed AA., (2018), CLINICAL CANCER RESEARCH, 24, 18 - 18

Somatic POLE exonuclease domain mutations are early events in sporadic endometrial and colorectal carcinogenesis, determining driver mutational landscape, clonal neoantigen burden and immune response.

Temko D. et al, (2018), J Pathol, 245, 283 - 296

The Oxford Ovarian Cancer Predict Chemotherapy Response (OXO-PCR) study: Understanding the genomic drivers of primary chemotherapy-resistant microscopic residual disease

Artibani M. et al, (2018), CANCER RESEARCH, 78

Clinically actionable mutation profiles in patients with cancer identified by whole-genome sequencing.

Schuh A. et al, (2018), Cold Spring Harb Mol Case Stud, 4

Genome and epigenome engineering CRISPR toolkit for in vivo modulation of cis-regulatory interactions and gene expression in the chicken embryo.

Williams RM. et al, (2018), Development, 145

Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation.

Zheng Y. et al, (2018), Nat Commun, 9

Engineering Synthetic Signaling Pathways with Programmable dCas9-Based Chimeric Receptors.

Baeumler TA. et al, (2017), Cell Rep, 20, 2639 - 2653

Load More

Include forthcoming?